# BHVN catalysts: Biohaven Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/bhvn/catalysts

> Biohaven Ltd. (BHVN) has 14 upcoming catalysts. The next is the BHV-7000 primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Biohaven Ltd. |
| Ticker | BHVN (NYSE) |
| SEC CIK | 1935979 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/bhvn |

## Cash runway

Cash $161.1M as of 2026-09-30; quarterly burn $106.9M; about 4.5 months of runway at that rate (XBRL company facts, accession 0001935979-26-000092).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2022 | [BHV-2000 trial start](https://sec-api.dev/pdufa/bhv-2000) | BHVN |  | completed | "In July 2022, we commenced enrollment in a Phase 3 clinical trial of BHV-2000 assessing the efficacy and safety of taldefgrobep alfa in Spinal Muscular Atrophy ("SMA")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000085/bhvn-20240930.htm)) |
| Sep 2022 | [Verdiperstat topline data readout](https://sec-api.dev/pdufa/verdiperstat) | BHVN | participants with ALS | completed, negative | "In September 2022, we reported negative topline results from the Phase 2/3 HEALEY ALS Platform trial evaluating verdiperstat compared to placebo for the treatment of participants with ALS." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000015/bhvn-20241231.htm)) |
| Jul 2023 | [VYGLXIA (troriluzole) NDA/BLA submission](https://sec-api.dev/pdufa/troriluzole) | BHVN |  | completed | "In July 2023, the FDA informed us that it would not review the submitted NDA application for troriluzole given that the study's primary endpoint was not met and thus, would not permit a substantive review." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm)) |
| Sep 2024 | [BH-2100 trial start](https://sec-api.dev/pdufa/bh-2100) | BHVN |  | completed | "In September 2024, we announced that we have initiated a Phase 2 study evaluating BH-2100 in the acute treatment of migraine." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000015/bhvn-20241231.htm)) |
| Sep 2024 | [BHV-2100 trial start](https://sec-api.dev/pdufa/bhv-2100) | BHVN |  | completed | "•Initiated Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine - In September 2024, the Company initiated a Phase 2 study of an orally administered TRPM3 antagonist, BHV-2100, in the acute treatment of migraine." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/a2024q3bhvnltdearningsprex.htm)) |
| Sep 2024 | [VYGLXIA (troriluzole) topline data readout](https://sec-api.dev/pdufa/troriluzole) | BHVN |  | completed, positive | "•Achieved positive topline results in pivotal study of troriluzole in SCA - In September 2024, the Company announced positive topline results from pivotal Study BHV4157-206-RWE demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/a2024q3bhvnltdearningsprex.htm)) |
| Q4 2024 | [VYGLXIA (troriluzole) interim data readout](https://sec-api.dev/pdufa/troriluzole) | BHVN |  | scheduled | "•Two Phase 3 trials with troriluzole in OCD; expect to conduct interim analysis of the second Phase 3 OCD trial in 4Q 2024 and report topline data from first Phase 3 OCD trial in 1H 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/a2024q3bhvnltdearningsprex.htm)) |
| Q4 2024 | [BHV-1600 trial start](https://sec-api.dev/pdufa/bhv-1600) | BHVN |  | scheduled | "We expect to initiate Phase 1 studies of BHV-1600 in the fourth quarter of 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000085/bhvn-20240930.htm)) |
| Q4 2024 | [TRAP (nephropathy) trial start](https://sec-api.dev/pdufa/nephropathy) | BHVN |  | scheduled | "We expect to initiate Phase 1 studies of BHV-1400 in the fourth quarter of 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000085/bhvn-20240930.htm)) |
| Q4 2024 | [VYGLXIA (troriluzole) topline data readout](https://sec-api.dev/pdufa/troriluzole) | BHVN |  | scheduled | "•Taldefgrobep alfa, a myostatin-inhibitor, Phase 3 topline data in spinal muscular atrophy (SMA) in 4Q 2024 and Phase 2 trial protocol in obesity expected in 4Q 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/a2024q3bhvnltdearningsprex.htm)) |
| Q4 2024 | [BHV-1310 trial start](https://sec-api.dev/pdufa/bhv-1310) | BHVN |  | scheduled | "We expect to initiate Phase 1 studies of BHV-1310 in the fourth quarter of 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000085/bhvn-20240930.htm)) |
| November 12, 2024 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/a2024q3bhvnltdearningsprex.htm)) |
| 2025 | [BHV-1510 trial start](https://sec-api.dev/pdufa/bhv-1510) | BHVN | urothelial cancer & other tumors | scheduled | "In oncology, interim Phase 1 data remain on track for 2025 with our lead clinical Trop-2 antibody drug conjugate ("ADC") program, BHV-1510, and initiation of a Phase 1 study with the field's first FGFR3 ADC, BHV-1530, for patients with urothelial cancer & other tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/a2025q1bhvnltdearningsprex.htm)) |
| 1H 2025 | [Biohaven Ltd. topline data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | scheduled | "•Pivotal topline data from two Phase 3 OCD trials expected in 1H 2025 and 2H 2025, respectively." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/a2025q1bhvnltdearningsprex.htm)) |
| 1H 2025 | [VYGLXIA (troriluzole) topline data readout](https://sec-api.dev/pdufa/troriluzole) | BHVN |  | scheduled | "We also look forward to delivering key clinical readouts, including pivotal topline data with troriluzole in obsessive compulsive disorder in 1H 2025 and with our selective Kv7 activator BHV-7000 in major depressive disorder ("MDD") in 2H 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/a2025q1bhvnltdearningsprex.htm)) |
| 1H 2025 | [Bhv-8000 10mg trial start](https://sec-api.dev/pdufa/bhv-8000) | BHVN |  | scheduled | "We anticipate beginning Phase 2/3 clinical trials with BHV-8000 in the first half of 2025 targeting" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000085/bhvn-20240930.htm)) |
| 1H 2025 | [BHV-2100 trial start](https://sec-api.dev/pdufa/bhv-2100) | BHVN |  | scheduled | "•Taldefgrobep alfa (novel myostatin inhibitor): Expect FDA meeting to discuss SMA registrational path in 1H 2025; separately initiating taldefgrobep alfa Phase 2 study in obesity in 1H 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/a2024q4bhvnltdearningsprex.htm)) |
| 1H 2025 | [Opakalim topline data readout](https://sec-api.dev/pdufa/opakalim) | BHVN |  | scheduled | "Differentiated profile vs. antipsychotics, lithium, and ASMs Acute bipolar mania topline results expected in 1H 2025 Topline results expected in 2H 2025 1st focal epilepsy study topline results expected in 1H 2026 Pivotal topline results for BHV-7000 development program expected within the next yearNEWS BREAKING" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000008/biohavenjpm2025jan12fina.htm)) |
| Feb 2025 | [VYGLXIA (troriluzole) NDA/BLA acceptance](https://sec-api.dev/pdufa/troriluzole) | BHVN |  | completed | "In February 2025, the FDA accepted for review our NDA for troriluzole for the treatment of adult patients with SCA and granted priority review." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm)) |
| Mar 2025 | [Opakalim topline data readout](https://sec-api.dev/pdufa/opakalim) | BHVN |  | completed, negative | "For example, in March 2025, we reported negative topline results from our Phase 2/3 clinical trial with opakalim for the acute treatment of manic episodes associated with bipolar disorder." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm)) |
| March 3, 2025 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/a2024q4bhvnltdearningsprex.htm)) |
| mid-2025 | [BHV-1310 trial start](https://sec-api.dev/pdufa/bhv-1310) | BHVN |  | scheduled | "Expect to initiate Phase 2 study in Graves' disease in mid-2025, and additional programs in rheumatoid arthritis and myasthenia gravis continue to be pursued." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/a2024q4bhvnltdearningsprex.htm)) |
| mid-2025 | [MoDE (BHV-1300) trial start](https://sec-api.dev/pdufa/bhv-1300) | BHVN |  | scheduled | "We plan to initiate a Phase 2 study of BHV-1300 in Graves' disease in mid-2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000015/bhvn-20241231.htm)) |
| May 2025 | [BHV-1530 trial start](https://sec-api.dev/pdufa/bhv-1530) | BHVN |  | completed | "•First patient dosed with Biohaven's TopoIx ADC, BHV-1530: In May 2025, the Company commenced dosing with BHV-1530, a potential first-in-class fibroblast growth factor receptor 3 (FGFR3)-directed ADC which utilizes the proprietary Topolx payload." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/a2025q2bhvnearningsprex991.htm)) |
| May 12, 2025 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/a2025q1bhvnltdearningsprex.htm)) |
| May 14, 2025 | [VYGLXIA (troriluzole) PDUFA date](https://sec-api.dev/pdufa/troriluzole) | BHVN | spinocerebellar ataxia | scheduled | "On May 14, 2025, Biohaven Ltd. (the "Company" or "Biohaven") issued a press release announcing that the Division of Neurology 1 (the "Division") within the U.S. Food and Drug Administration's ("FDA") Office of Neuroscience informed the Company that they are extending the Prescription Drug User Fee Act ("PDUFA") date for the troriluzole new drug application (the "NDA") for the treatment of spinocerebellar ataxia by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000056/bhvn-20250514.htm)) |
| 2H 2025 | [Opakalim topline data readout](https://sec-api.dev/pdufa/opakalim) | BHVN |  | scheduled | "We also look forward to delivering key clinical readouts, including pivotal topline data with troriluzole in obsessive compulsive disorder in 1H 2025 and with our selective Kv7 activator BHV-7000 in major depressive disorder ("MDD") in 2H 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/a2025q1bhvnltdearningsprex.htm)) |
| 2H 2025 | [Biohaven Ltd. topline data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | scheduled | "•Pivotal major depressive disorder topline results expected in 2H 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/a2024q4bhvnltdearningsprex.htm)) |
| Q3 2025 | [VYGLXIA (troriluzole) PDUFA date](https://sec-api.dev/pdufa/troriluzole) | BHVN |  | scheduled | "•Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/a2024q4bhvnltdearningsprex.htm)) |
| 2H 2025 | [Biohaven Ltd. topline data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | scheduled | "We expect to report topline data from the second Phase 3 study in OCD in the second half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000015/bhvn-20241231.htm)) |
| 2H 2025 | [Biohaven Ltd. topline data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | scheduled | "We expect to report topline results from the study in the second half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000092/bhvn-20250930.htm)) |
| August 11, 2025 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/a2025q2bhvnearningsprex991.htm)) |
| Q4 2025 | [VYGLXIA (troriluzole) PDUFA date](https://sec-api.dev/pdufa/troriluzole) | BHVN |  | scheduled | "•VYGLXIA NDA for spinocerebellar ataxia (SCA) PDUFA date 4Q2025, completed clinical trial inspections by FDA without observations or findings, and filing review remains ongoing" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/a2025q2bhvnearningsprex991.htm)) |
| October 27, 2025 | [VYGLXIA (troriluzole) primary completion](https://sec-api.dev/pdufa/troriluzole) | BHVN | Obsessive-Compulsive Disorder | completed | "NCT04641143 (Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Biohaven Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04641143)) |
| Nov 2025 | [VYGLXIA (troriluzole) complete response letter (CRL)](https://sec-api.dev/pdufa/troriluzole) | BHVN |  | completed, complete response letter | "In November 2025, we received a Complete Response Letter ("CRL") for the NDA seeking approval of troriluzole for SCA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm)) |
| November 4, 2025 | [Nda210862 complete response letter (CRL)](https://sec-api.dev/pdufa/nda210862) | BHVN |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 11/04/2025 for NDA 210862 to Biohaven Therapeutics, Ltd.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA210862_20251104.pdf%22)) |
| November 7, 2025 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Major Depressive Disorder | completed | "NCT06419608 (Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-07 (ACTUAL); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06419608)) |
| November 10, 2025 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000090/a2025q3bhvnearningsprex991.htm)) |
| 1H 2026 | [Opakalim topline data readout](https://sec-api.dev/pdufa/opakalim) | BHVN |  | scheduled | "1st focal epilepsy study topline results expected 1H 2026 KEY POINT GABA, γ-aminobutyric acid." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000058/biohaveninvestorpresenta.htm)) |
| 1H 2026 | [Biohaven Ltd. interim data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | scheduled | "•Continue two Phase 2/3 studies in focal epilepsy with initial top-line results expected in 1H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000090/a2025q3bhvnearningsprex991.htm)) |
| February 13, 2026 | [Troriluzole (bhv-4157) primary completion](https://sec-api.dev/pdufa/troriluzole-bhv-4157) | BHVN | Obsessive Compulsive Disorder | withdrawn | "NCT04708834 (Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-02-13 (ACTUAL); Lead Sponsor Biohaven Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04708834)) |
| March 2, 2026 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000022/a2025q4bhvnearningsprex991.htm)) |
| March 12, 2026 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Generalized Epilepsy | withdrawn | "NCT06425159 (A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06425159)) |
| March 18, 2026 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Major Depressive Disorder | completed | "NCT06423781 (Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-18 (ACTUAL); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06423781)) |
| May 2026 | [MoDE (BHV-1300) trial start](https://sec-api.dev/pdufa/bhv-1300) | BHVN | Graves' disease | completed | "•Presented new patient data from the MoDE platform in Graves' disease; initiated pivotal study: In May 2026, the Company presented new clinical data from an ongoing Phase 1b study of BHV-1300 in patients with Graves' disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/a2026q2bhvnearningsprex991.htm)) |
| May 4, 2026 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/a2026q1bhvnearningsprex991.htm)) |
| 2H 2026 | [Biohaven Ltd. topline data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | scheduled | "The study is fully enrolled and randomized, dosing is ongoing, and topline data remains on track for the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000093/a2026q3bhvnearningsprex991.htm)) |
| 2H 2026 | [Opakalim topline data readout](https://sec-api.dev/pdufa/opakalim) | BHVN | focal epilepsy | scheduled | "•Ongoing clinical progress with opakalim across multiple epilepsy types; pivotal readout on track for 2H 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/a2026q2bhvnearningsprex991.htm)) |
| 2H 2026 | [Biohaven Ltd. topline data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN | overweight and obesity, with topline results | scheduled | "◦Phase 2 obesity study with myostatin-activin pathway inhibitor, taldefgrobep alfa, completed enrollment and topline data expected in 2H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/a2026q1bhvnearningsprex991.htm)) |
| 2H 2026 | [Biohaven Ltd. topline data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | scheduled | "In the second half of 2026, we expect to report pivotal data from our epilepsy program and topline results from our obesity program."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/a2026q1bhvnearningsprex991.htm)) |
| 2H 2026 | [Biohaven Ltd. interim data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | scheduled | "•Continue two Phase 2/3 studies in focal epilepsy; initial topline results for the first study expected in 2H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/a2026q1bhvnearningsprex991.htm)) |
| 2H 2026 | [MoDE (BHV-1300) trial start](https://sec-api.dev/pdufa/bhv-1300) | BHVN |  | scheduled | "The Company intends to initiate a pivotal study with BHV-1300 in Graves' disease in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000022/a2025q4bhvnearningsprex991.htm)) |
| August 10, 2026 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/a2026q2bhvnearningsprex991.htm)) |
| September 2026 | [Taldefgrobep alfa primary completion](https://sec-api.dev/pdufa/taldefgrobep-alfa) | BHVN | Obesity; Overweight | delayed | "NCT07281495 (Taldefgrobep Alfa in Adults With Overweight and Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07281495)) |
| Sep to Dec 2026 | [Taldefgrobep alfa topline data readout](https://sec-api.dev/pdufa/taldefgrobep-alfa) | BHVN | Obesity; Overweight | scheduled | "NCT07281495 (Taldefgrobep Alfa in Adults With Overweight and Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07281495)) |
| Q4 2026 | [TRAP (nephropathy) trial start](https://sec-api.dev/pdufa/nephropathy) | BHVN | IgAN, and plan to initiate a pivotal trial in 2026 using urine protein-creatinine ratio | scheduled | "•On track to initiate the pivotal Phase 3 trial of BHV-1400, a TRAP™ extracellular degrader targeting galactose-deficient IgA1 (Gd-IgA1), in IgA nephropathy (IgAN) during 4Q 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000093/a2026q3bhvnearningsprex991.htm)) |
| October 2026 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Focal Epilepsy | delayed | "NCT06309966 (Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06309966)) |
| Oct 2026 to Jan 2027 | [BHV-7000 topline data readout](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Focal Epilepsy | scheduled | "NCT06309966 (Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06309966)) |
| October 22, 2026 | [VYGLXIA (troriluzole) NDA/BLA acceptance](https://sec-api.dev/pdufa/troriluzole) | BHVN | spinocerebellar ataxia | completed | "On October 22, 2026, we announced that the FDA has accepted for review our new drug application ("NDA") resubmission for Vyglxia (troriluzole) for the treatment of spinocerebellar ataxia ("SCA")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000092/bhvn-20260930.htm)) |
| October 29, 2026 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000093/a2026q3bhvnearningsprex991.htm)) |
| December 2026 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Focal Epilepsy | scheduled | "NCT06132893 (A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132893)) |
| Dec 2026 to Mar 2027 | [BHV-7000 topline data readout](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Focal Epilepsy | scheduled | "NCT06132893 (A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132893)) |
| December 2026 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Focal Epilepsy | scheduled | "NCT06443463 (Long-term Safety and Tolerability of BHV-7000): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06443463)) |
| Dec 2026 to Mar 2027 | [BHV-7000 topline data readout](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Focal Epilepsy | scheduled | "NCT06443463 (Long-term Safety and Tolerability of BHV-7000): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06443463)) |
| 2H 2027 | [Biohaven Ltd. topline data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | scheduled | "•Phase 2 study in obesity remains ongoing with planned addition of GLP-1 combination cohort; topline data expected in 2H 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000093/a2026q3bhvnearningsprex991.htm)) |
| 2H 2027 | [Biohaven Ltd. topline data readout](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | scheduled | "As a result of the amended study design, we now anticipate topline data from the monotherapy and combination therapy portions of the trial in 2H 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000093/a2026q3bhvnearningsprex991.htm)) |
| August 2027 | [Bhv-8000 10mg primary completion](https://sec-api.dev/pdufa/bhv-8000) | BHVN | Parkinson Disease | scheduled | "NCT06976268 (A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06976268)) |
| Aug to Nov 2027 | [Bhv-8000 10mg topline data readout](https://sec-api.dev/pdufa/bhv-8000) | BHVN | Parkinson Disease | scheduled | "NCT06976268 (A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06976268)) |
| January 2028 | [MoDE (BHV-1300) primary completion](https://sec-api.dev/pdufa/bhv-1300) | BHVN | Graves Disease | scheduled | "NCT07661056 (Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07661056)) |
| Jan to Apr 2028 | [MoDE (BHV-1300) topline data readout](https://sec-api.dev/pdufa/bhv-1300) | BHVN | Graves Disease | scheduled | "NCT07661056 (Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07661056)) |
| September 2028 | [BHV-1400 primary completion](https://sec-api.dev/pdufa/bhv-1400) | BHVN | IgA Nephropathy | scheduled | "NCT07642050 (A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07642050)) |
| Sep to Dec 2028 | [BHV-1400 topline data readout](https://sec-api.dev/pdufa/bhv-1400) | BHVN | IgA Nephropathy | scheduled | "NCT07642050 (A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07642050)) |
| December 2028 | [MoDE (BHV-1300) primary completion](https://sec-api.dev/pdufa/bhv-1300) | BHVN | Graves' Disease | scheduled | "NCT07901244 (An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07901244)) |
| Dec 2028 to Mar 2029 | [MoDE (BHV-1300) topline data readout](https://sec-api.dev/pdufa/bhv-1300) | BHVN | Graves' Disease | scheduled | "NCT07901244 (An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07901244)) |

## Drugs

- [BH-2100](https://sec-api.dev/pdufa/bh-2100): 
- [MoDE (BHV-1300)](https://sec-api.dev/pdufa/bhv-1300): graves' disease, Graves Disease
- [BHV-1310](https://sec-api.dev/pdufa/bhv-1310): 
- [BHV-1400](https://sec-api.dev/pdufa/bhv-1400): IgA Nephropathy
- [BHV-1510](https://sec-api.dev/pdufa/bhv-1510): urothelial cancer & other tumors
- [BHV-1530](https://sec-api.dev/pdufa/bhv-1530): 
- [BHV-1600](https://sec-api.dev/pdufa/bhv-1600): 
- [BHV-2000](https://sec-api.dev/pdufa/bhv-2000): 
- [BHV-2100](https://sec-api.dev/pdufa/bhv-2100): 
- [BHV-7000](https://sec-api.dev/pdufa/bhv-7000): Focal Epilepsy, Generalized Epilepsy, Major Depressive Disorder
- [Bhv-8000 10mg](https://sec-api.dev/pdufa/bhv-8000): Parkinson Disease
- [Nda210862](https://sec-api.dev/pdufa/nda210862): 
- [TRAP (nephropathy)](https://sec-api.dev/pdufa/nephropathy): igan, and plan to initiate a pivotal trial in 2026 using urine protein-creatinine ratio
- [Opakalim](https://sec-api.dev/pdufa/opakalim): focal epilepsy
- [Taldefgrobep alfa](https://sec-api.dev/pdufa/taldefgrobep-alfa): Obesity
- [VYGLXIA (troriluzole)](https://sec-api.dev/pdufa/troriluzole): spinocerebellar ataxia, Obsessive-Compulsive Disorder
- [Troriluzole (bhv-4157)](https://sec-api.dev/pdufa/troriluzole-bhv-4157): Obsessive Compulsive Disorder
- [Verdiperstat](https://sec-api.dev/pdufa/verdiperstat): participants with als

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/bhvn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BHVN catalysts: Biohaven Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/bhvn/catalysts

```bibtex
@misc{secapidev_companies_bhvn_catalysts_20261116,
  title        = {BHVN catalysts: Biohaven Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/bhvn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_bhvn_catalysts_20261116","title":"BHVN catalysts: Biohaven Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/bhvn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
